What's on this Page
What is Comvax
Comvax is a bivalent vaccine made up of the antigenic components present in PedvaxHIB (Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate)) and Recombivax HB (hepatitis B vaccine, recombinant).
Comvax is indicated for vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants 6 weeks to 15 months of age born of HBsAg negative mothers.
The combination provides a convenient dosage form for infants who are scheduled to receive both vaccines at the same time. A 3-dose primary immunization series is required.
Indications
- Haemophilus influenzae type b prophylaxis
- hepatitis B prophylaxis
Side Effects
- anaphylactoid reactions
- angioedema
- anorexia
- candidiasis
- cough
- diarrhea
- drowsiness
- erythema
- erythema multiforme
- fever
- Guillain-Barre syndrome
- inconsolable crying
- infection
- injection site reaction
- irritability
- nasal congestion
- rash
- rhinorrhea
- seizures
- Stevens-Johnson syndrome
- thrombocytopenia
- urticaria
- vomiting
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- agammaglobulinemia
- anticoagulant therapy
- breast-feeding
- children
- coagulopathy
- corticosteroid therapy
- fever
- geriatric
- hemophilia
- human immunodeficiency virus (HIV) infection
- hypogammaglobulinemia
- immunosuppression
- infants
- infection
- intravenous administration
- latex hypersensitivity
- neonates
- neoplastic disease
- pregnancy
- radiation therapy
- severe combined immunodeficiency (SCID)
- subcutaneous administration
- thrombocytopenia
- vitamin K deficiency
- yeast hypersensitivity
Interactions
- Hepatitis B Immune Globulin, HBIG
- Ocrelizumab
- Siponimod
